Modulation of immune responses using adjuvants to facilitate therapeutic vaccination

buir.contributor.authorGürsel, İhsan
dc.citation.epage190en_US
dc.citation.issueNumber1en_US
dc.citation.spage169en_US
dc.citation.volumeNumber296en_US
dc.contributor.authorSchijns, V.
dc.contributor.authorFernández‐Tejada, A.
dc.contributor.authorBarjaktarović, Ž.
dc.contributor.authorBouzalas, I.
dc.contributor.authorBrimnes, J.
dc.contributor.authorChernysh, S.
dc.contributor.authorGizurarson, S.
dc.contributor.authorGürsel, İhsan
dc.contributor.authorJakopin, Ž.
dc.contributor.authorLawrenz, M.
dc.contributor.authorNativi, C.
dc.contributor.authorPaul, S.
dc.contributor.authorPedersen, G. K.
dc.contributor.authorRosano, C.
dc.contributor.authorRuiz‐de‐Angulo, A.
dc.contributor.authorSlütter, B.
dc.contributor.authorThakur, A.
dc.contributor.authorChristensen, D.
dc.contributor.authorLavelle, Ed. C.
dc.date.accessioned2021-02-10T11:52:03Z
dc.date.available2021-02-10T11:52:03Z
dc.date.issued2020
dc.departmentDepartment of Molecular Biology and Geneticsen_US
dc.description.abstractTherapeutic vaccination offers great promise as an intervention for a diversity of infectious and non‐infectious conditions. Given that most chronic health conditions are thought to have an immune component, vaccination can at least in principle be proposed as a therapeutic strategy. Understanding the nature of protective immunity is of vital importance, and the progress made in recent years in defining the nature of pathological and protective immunity for a range of diseases has provided an impetus to devise strategies to promote such responses in a targeted manner. However, in many cases, limited progress has been made in clinical adoption of such approaches. This in part results from a lack of safe and effective vaccine adjuvants that can be used to promote protective immunity and/or reduce deleterious immune responses. Although somewhat simplistic, it is possible to divide therapeutic vaccine approaches into those targeting conditions where antibody responses can mediate protection and those where the principal focus is the promotion of effector and memory cellular immunity or the reduction of damaging cellular immune responses as in the case of autoimmune diseases. Clearly, in all cases of antigen‐specific immunotherapy, the identification of protective antigens is a vital first step. There are many challenges to developing therapeutic vaccines beyond those associated with prophylactic diseases including the ongoing immune responses in patients, patient heterogeneity, and diversity in the type and stage of disease. If reproducible biomarkers can be defined, these could allow earlier diagnosis and intervention and likely increase therapeutic vaccine efficacy. Current immunomodulatory approaches related to adoptive cell transfers or passive antibody therapy are showing great promise, but these are outside the scope of this review which will focus on the potential for adjuvanted therapeutic active vaccination strategies.en_US
dc.description.sponsorshipEuropean Cooperation in Science and Technology. Grant Number: CA16231en_US
dc.identifier.doi10.1111/imr.12889en_US
dc.identifier.issn0105-2896
dc.identifier.urihttp://hdl.handle.net/11693/55041
dc.language.isoEnglishen_US
dc.publisherWileyen_US
dc.relation.isversionofhttps://dx.doi.org/10.1111/imr.12889en_US
dc.source.titleImmunological Reviewsen_US
dc.subjectAdjuvanten_US
dc.subjectAutoimmunityen_US
dc.subjectCanceren_US
dc.subjectCellular immunityen_US
dc.subjectTherapeuticen_US
dc.subjectVaccineen_US
dc.titleModulation of immune responses using adjuvants to facilitate therapeutic vaccinationen_US
dc.typeReviewen_US

Files

Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Modulation_of_immune_responses_using_adjuvants_to_facilitate_therapeutic_vaccination.pdf
Size:
1.33 MB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: